Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of AMG 655 and AMG 479 in metastatic colorectal cancer
2008-005301-19Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing AMG 655 + AMG 479 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Mar 2009; status: completed.
02
Drugs
conatumumabganitumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-005301-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005301-19.